Radioligand-binding study of noribogaine, a likely metabolite of ibogaine.
S M Pearl, K Herrick-Davis, M Teitler, S D Glick
Brain research March 27, 1995 DOI: 10.1016/0006-8993(95)00123-8 via PubMed
Summary
AI-generated from the abstractNoribogaine, a suspected metabolite of ibogaine, binds more strongly than ibogaine to all three types of opioid receptors. Ibogaine had highest affinity for kappa receptors, less for mu, and no measurable affinity for delta receptors. Noribogaine showed higher affinity for kappa, mu, and delta receptors, suggesting it is active in the body and may contribute to ibogaine's effects.
Study at a glance
| Characteristics | Radioligand-binding study Peer reviewed |
|---|---|
| Citations | 78 |
| Key finding | Noribogaine has higher affinity than ibogaine for kappa, mu, and delta opioid receptors, suggesting it may contribute to ibogaine's pharmacological effects. |
Abstract
Radioligand-binding studies were performed to ascertain the actions of noribogaine, a suspected metabolite of ibogaine, on opioid receptors. Consistent with previous results, ibogaine showed highest affinity for kappa opioid receptors (Ki = 3.77 +/- 0.81 microM), less affinity for mu receptors (Ki = 11.04 +/- 0.66 microM) and no affinity for delta receptors (Ki > 100 microM). Noribogaine showed a higher affinity than ibogaine for all of the opioid receptors: kappa Ki = 0.96 +/- 0.08 microM, mu Ki = 2.66 +/- 0.62 microM and delta Ki = 24.72 +/- 2.26 microM. These data suggest that noribogaine is active in vivo and that it may contribute to ibogaine's pharmacological effects.